Company intelligence / Profile preview

Tiburio Therapeutics

Cambridge, Massachusetts, United Stateslundbeckfonden.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Tiburio Therapeutics developed two clinical-stage dopamine-somatostatin chimeric compounds licensed from Ipsen. TBR‑760 targeted non-functioning pituitary adenomas and entered Phase II enabling studies, while TBR‑065 completed a Phase I trial with further rare endocrine indications under exploration. The company raised $31M in Series A funding to support these programs before being acquired by Mallinckrodt Pharmaceuticals.

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecules (specifically dopamine-somatostatin chimeric compounds)
Industry: Biotech

Drug pipeline

1 asset

onzigolide

Partnerships

Cydan (orphan drug accelerator/launch partner)Ipsen (licensed lead compounds from Ipsen)

Beyond the preview

Go deeper on Tiburio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiburio Therapeutics.

Explore the full profile